Jade Biosciences, Inc. (JBIO)

Jade Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
Cash & Equivalents	69.39
Cash & Short-Term Investments	69.39
Prepaid Expenses	0.27
Total Current Assets	69.65
Other Long-Term Assets	3.15
Total Assets	72.8
Accounts Payable	1.29
Accrued Expenses	9.63
Other Current Liabilities	1.08
Total Current Liabilities	12
Long-Term Debt	107.6
Total Liabilities	119.6
Common Stock	0
Additional Paid-In Capital	0.18
Retained Earnings	-46.98
Total Common Equity	-46.8
Shareholders' Equity	-46.8
Total Liabilities & Equity	72.8
Total Debt	107.6
Net Cash (Debt)	-38.21
Net Cash Per Share	-7.64
Filing Date Shares Outstanding	5.82
Total Common Shares Outstanding	5.82
Working Capital	57.66
Book Value Per Share	-8.04
Tangible Book Value	-46.8
Tangible Book Value Per Share	-8.04

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q